EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

COVID-19 disruption to cervical cancer screening in England

Alejandra Castanon iD, Matejka Rebolj iD, Francesca Pesola, Philippa Pearmain, Ruth Stubbs

Journal of Medical Screening · 2022-09 · 29 (3) · 203-208

DOI: 10.1177/09691413221090892 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Screening, online erschienen am 04.04.2022. Verfasst von Alejandra Castanon und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Cancer & Pharmaceutical Sciences, 4616King's College London, London, UK. Hauptthemen laut MEDLINE: COVID-19, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In England, routine invitations for cervical screening were reduced between April 2020 and June 2020 due to the COVID-19 pandemic. We quantify the impact of COVID-19 disruptions on attendance and excess diagnoses of cervical cancer (CC).

Methods

Using Public Health England CC screening data on laboratory samples received in 2018 as a baseline we quantify the reduction in screening attendances due to the COVID-19 pandemic between April 2020 and March 2021 for women aged 25–64. We model the impact on excess CC diagnoses assuming once invitations resume 87.5% of women attend within 12 months and 12.5% delay screening for 3 or 5 years (depending on age).

Results

The number of samples received at laboratories was 91% lower than expected during April, 85% during May and 43% during June 2020 compared to the same period in 2018. Although on average laboratories received 12.6% more samples between August 2020 and April 2021 than over the same months in 2018, by April 2021 there was a short fall of 200,949 samples (6.4% fewer than in 2018). An excess of 41 CC (4.0 per 100,000 women with a maximum screening delay of 12 months) are predicted to occur among the estimated 1,024,794 women attending this screening round with a delay. An excess of 60 CC (41.0 per 100,000 women) are predicted to occur among the estimated 146,391 women who do not attend this screening round.

Conclusion

Prompt restoration of cervical screening services limited the impact on excess CC diagnoses. However, in 2020 a 6.4% shortfall of screening samples was observed. Every effort should be made to reassure these women that services are open and safe to attend.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Uterine Cervical NeoplasmsEarly Detection of CancerEnglandFemaleHumansMass ScreeningPandemics

Stichwörter der Autor:innen

COVID-19cervical cancer screeningexcess cervical cancerscreening delays

Autor:innen und Institutionen

  • School of Cancer & Pharmaceutical Sciences, 4616King's College London, London, UK.
  • Screening Quality Assurance Service, NHS England and NHS Improvement, London, UK.
  • Public Health Commissioning and Operations, NHS England and NHS Improvement, London, UK.

ORCID-Profile: Alejandra Castanon, Matejka Rebolj

Förderung

  • Cancer Research UK

Zitieren

APA

Castanon, A., Rebolj, M., Pesola, F., Pearmain, P., & Stubbs, R. (2022). COVID-19 disruption to cervical cancer screening in England. Journal of Medical Screening, 29(3), 203-208. https://doi.org/10.1177/09691413221090892

Vancouver

Castanon A, Rebolj M, Pesola F, Pearmain P, Stubbs R. COVID-19 disruption to cervical cancer screening in England. Journal of Medical Screening. 2022;29(3):203-208. doi:10.1177/09691413221090892

BibTeX
@article{Castanon2022,
  author = {Castanon, Alejandra and Rebolj, Matejka and Pesola, Francesca and Pearmain, Philippa and Stubbs, Ruth},
  title = {COVID-19 disruption to cervical cancer screening in England},
  journal = {Journal of Medical Screening},
  year = {2022},
  volume = {29},
  number = {3},
  pages = {203--208},
  doi = {10.1177/09691413221090892}
}
Kostenlos starten →